T he renin-angiotensin system is one of the major regulators of blood pressure and fluid and electrolyte homeostasis. Its primary components are 1) angiotensinogen, a large globular protein that serves as the substrate for 2) renin, the enzyme that catalyzes the proteolytic conversion of angiotensinogen to the decapeptide angiotensin I; 3) angiotensin converting enzyme, a dipeptidyl carboxypeptidase that converts angiotensin I to the octapeptide angiotensin II; 4) angiotensin II itself; and 5) the angiotensin II receptor, responsible for transducing the cellular effects of angiotensin II (Figure 1) . Binding of the final product of this enzymatic cascade (angiotensin II) to its receptor mediates vasoconstriction and aldosterone and catecholamine release, as well as drinking, secretion of prolactin and adrenocorticotrophic hormone, and glycogenolysis. ' Historically, this hormonal system has been viewed as a systemic one, the various components of which were derived from different organs and were delivered to their site of action by the circulatory system. More recent evidence using molecular and biochemical approaches to angiotensin physiology raises the possibility that there are distinct, local renin-angiotensin systems with different mechanisms of regulation. Local reninangiotensin systems have been proposed in the vasculature,2 brain,3 heart,4 and kidney,5 but incontrovertible evidence for the existence of all components of the system in physiologically relevant amounts and relationships remains elusive. Although the role of these putative local systems is unknown, it is interesting to speculate that they may serve as a mechanism for limiting the actions of angiotensin II to a specific organ system or physiological event.
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Molecular biological and sophisticated biochemical measurements have opened a new era in our understanding of this important hormonal system. Not only have these techniques brought to the forefront the controversy surrounding the anatomic location of the individual components, but they also have provided insight into the regulation of the expression and formation of each protein or peptide and opened new strategies for therapeutic manipulation. The recent cloning of the AT, receptor6,7 and the development of pharmacological agents that distinguish this receptor from the closely related, but structurally distinct, AT2 binding site provide a fertile and relatively unexplored field for further research. This review summarizes our view of the important advances in molecular biology of the four major components of the renin-angiotensin system (renin, angiotensinogen [and, by default, angiotensins I and II], angiotensin converting enzyme, and the AT receptors) and touches on their implications in the study of vascular diseases.
Renin Protein
Renin is a glycoproteolytic enzyme that is responsible for the first step in the formation of angiotensin II. It has been studied extensively over the years, but the recent purification and cloning of human, mouse, and rat renins have led to an explosion of information concerning its structure and function. Renin is a singlechain aspartyl protease of molecular weight 37-40 kd and pI 5.2-5.8.8 Its primary structure contains double domains; that is, the amino-and carboxyl-termini contain areas of similar sequence,9 forming a two-lobed structure surrounding the active site. This catalytic region contains two critical aspartic acid residues,10 one contributed by each half of the molecule. In contrast to other proteases of this class, renin is highly specific for its substrate, angiotensinogen, and is most active at neutral pH. 8 The main source of renin is the juxtaglomerular cells of the afferent arterioles of the kidney.1" Translation of renin mRNA yields preprorenin, which then undergoes cotranslational removal of a signal peptide and glycosylation during transport through the rough endoplasmic reticulum to become prorenin.8 Prorenin can be either constitutively secreted from the Golgi apparatus or packaged in immature granules and secreted in a regulated fashion. Some conversion of prorenin to renin by removal of a 43-amino acid segment can occur in these granules, so both prorenin and renin are secreted. However, because prorenin is the major circulating form of renin, the primary site of conversion of plasma prorenin to renin remains unclear. Prorenin The availability of cDNA probes for renin has spawned renewed investigation into the possibility of local renin-angiotensin systems. In transgenic mice expressing the human renin gene, renin mRNA expression was found to be high in the kidney, adrenal, ovary, testis, lung, and adipose tissue and low in the heart and submandibular gland.18 Rat and mouse brain and heart express very low levels of renin, and renin message appears to be absent in the livers of these species. 8 Although prorenin mRNA is expressed only at very low levels19 or is absent20 in blood vessels, it has been postulated that the avid uptake of prorenin by blood vessels may result in local accumulation and activation of prorenin in this tissue. 26 Physiological studies of alterations in plasma levels of angiotensinogen have provided evidence for upregulation of this protein during pregnancy or estrogen therapy and in Cushing's syndrome and downregulation after thyroidectomy and in Addison's disease. 23 Increases in plasma levels ultimately were shown to be due to increased hepatic synthesis. These results were confirmed at the mRNA level, where it was shown that glucocorticoid, estrogen, and thyroid hormones increase angiotensinogen mRNA in rat hepatocytes. 27 These observations suggested that the 5' flanking region of the angiotensinogen gene might contain cis-acting regulatory elements that bind to receptors for the hormones whose levels are altered in these cases. Analysis of this region of the rat and human genes has shown consensus sequences for three glucocorticoid responsive elements (GRE), a thyroid hormone responsive element (TRE), and an estrogen responsive element (ERE) ( Figure  2 ).23,28.29 In addition, a viruslike enhancer element sequence (ENH) is present in the midrange of this region of the gene, and two promoter sequences, a TATA box and a CAT element, have been identified near the transcriptional start site.23 Deletion analysis of this region indicates that transcriptional activity is highly dependent on upstream (i.e., 5' of the transcriptional initiation site) cis-acting DNA elements, whereas the TATA element provides the minimal promoter function.29 These upstream sequences include two positive regulatory elements, two negative regulatory elements,28 and a homologous hepatic nuclear factor-1 (HNF-1)-like binding site, which functions as a tissuespecific enhancer region mediated by a nuclear transcription factor.28 Finally, the angiotensinogen gene contains an acute-phase response element (APRE) that binds to two types of nuclear proteins: tissue-specific nuclear factor KB (NFKB), a protein that purportedly is regulated by inflammatory mediators and oxidative stress, and a family of CCAAT/enhancer binding protein (c/EBP)-like constitutive binding proteins.30
Tissue Distribution and Regulation
As noted above, it is fairly well accepted that the major source of angiotensinogen is the liver. This has been confirmed by measurement of the distribution of angiotensinogen mRNA in various tissues. In the rat, the highest amount of angiotensinogen mRNA was found in the liver, but brain, spinal cord, aorta (smooth muscle and adventitia), and mesentery also expressed significant levels of this message.31 Low but detectable tensinogen is attached to a 24-or 33-amino acid signal levels were found in the kidney, adrenal, atria, lung, large intestine, stomach, and spleen, while angiotensinogen mRNA was absent in the pituitary, ventricle, testis, small intestine, and pancreas.31 In those tissues expressing low amounts of angiotensinogen mRNA, it has been suggested that the neural or vascular components of the tissue may be the ultimate source.
Similar to expression of renin mRNA, levels of angiotensinogen mRNA appear to be differentially regulated in various tissues. In the liver, there are two different polyadenylation signals, resulting in two possible 3 37 Angiotensin converting enzyme also is a member of the family of zinc metallopeptidases and contains a molar equivalent of zinc that functions in the hydrolytic step of the catalytic reaction.37,39 The enzyme consists of a single chain that is moderately hydrophobic and is predominately membrane bound. Sequence analysis of various angiotensin converting enzyme preparations has indicated that the protein is anchored to the plasma membrane at the C-terminus, although the precise mechanism is unknown.
Several approaches have been used to study the structural regulation of angiotensin converting enzyme activity. Although the sequence of angiotensin converting enzyme predicts the presence of two active sites, only one apparently is functional. 40 The active site contains four critical functional residues: tyrosine, arginine, glutamine, and lysine. 4 AUUUA motifs that are common to labile RNAs, 80 supporting the possibility that the human AT1 receptor is posttranscriptionally regulated.
Although some disagreement exists in the literature, Southern analysis of the rat and mouse genome suggests the presence of at least two genes for AT1 receptors.76,79 A typical Southern blot of rat genomic DNA is shown in Figure 5 . Digestion with XbaI or HindIII restriction enzymes followed by hybridization with a probe that anneals to a sequence that cannot be digested with these enzymes reveals two distinct bands, implying that there may be two distinct genes. Restriction mapping, differential hybridization, polymerase chain reaction amplification, and sequence analysis indicate that the AT1A and the AT1B receptors are encoded by two separate genes, which share a 94% amino acid sequence identity in the open reading frame but only a 35% identity in the 3' and 5' flanking regions. 79 Tissue Distribution and Regulation of the AT, Receptor Availability of pharmacological agents that differentially bind to AT1 and AT2 receptors and of specific mRNA probes for AT1A and AT18 receptors has helped to define AT1 receptor distribution. AT1A receptor mRNA is abundant in the liver, kidney, aorta, uterus, adrenals, ovary, spleen, and lung6 and is found in the hypothalamus and subfornical organ of the brain.81 AT1B receptor mRNA is found primarily in the pituitary, adrenal gland, kidney, uterus, and liver81,82 and is, perhaps significantly, absent from the heart, brain, and spleen. 83 The regulation of AT1 receptor expression is of intense current interest. Limited available evidence supports the notion that AT1 receptor expression is modulated by angiotensin II itself and cAMP and may be regulated by protein kinase C and tyrosine phosphorylation. Previous binding studies have shown that vascular angiotensin receptors undergo homologous downregulation,84 suggesting that angiotensin II may regulate the expression of its own receptor. Angiotensin II has been shown to reduce ATlA receptor mRNA expression by 50% after [4] [5] [6] hours in cultured vascular smooth muscle cells85 and mesangial cells.86 In contrast to these results, infusion of angiotensin II increased AT1 receptor mRNA expression in the adrenal gland but not that in aorta or kidney.87 Similar to the effects of angiotensin II on cultured cells, agents that elevate intracellular cAMP, including forskolin and cholera toxin, also cause receptor downregulation at the mRNA level.85 Other possible regulatory pathways are indicated by analysis of the amino acid sequence of the receptor. The presence of three potential sites for protein kinase C phosphorylation in the C-terminus of the receptor suggests that phosphorylation by this enzyme may also play a role in receptor regulation.65 To date, there is no direct evidence to support this possibility. Finally, the tyrosine residues present in the cytoplasmic tail of the receptor (Figure 4) Local Renin-Angiotensin System in the Vasculature
As indicated in the introduction, the existence of local renin-angiotensin systems is controversial. In this section, we review the evidence for the existence of a local vascular system. The data discussed are not necessarily applicable to the local systems proposed for the kidney and heart, but these have been reviewed elsewhere. 5, 96 Indirect evidence for a local vascular renin-angiotensin system has been derived from whole animal, isolated organ, and tissue culture studies. Thus, after blocking circulating angiotensin II with antibodies, infusion of captopril or the angiotensin II receptor antagonist saralasin was still effective in lowering blood pressure. 97 Furthermore, there is a demonstrable arteriovenous difference in angiotensin I levels even after captopril treatment, indicating turnover by the vasculature.98 In addition, the vascular wall was shown to contain a reninlike activity,99 and in the isolated, perfused rat hindquarter preparation, both angiotensin I and angiotensin II are generated.100 Finally, all the components of the renin-angiotensin system have been demonstrated by molecular biology techniques to be present in cultured endothelial and smooth muscle cells.10' '02
Evidence against the existence of a complete local renin-angiotensin system rests largely on the observation that bilateral nephrectomy causes a dramatic decrease in arterial renin activity, suggesting that the reninlike activity associated with the vascular wall is derived from uptake of circulating renin of renal origin.99103 In support of this, molecular biological techniques have demonstrated only low levels of renin mRNA in arterial tissue, '9,102 and in some studies, renin mRNA could not be detected at all. 20 Finally, it is unclear whether the angiotensinogen mRNA present in the vasculature is associated with smooth muscle and endothelium or merely with adherent adipose tissue.104
To unequivocally demonstrate a functional local reninangiotensin system, at least two requirements must be met. First, all components of the system (renin, angiotensinogen, angiotensin converting enzyme, and the final effector, the AT receptor) not only must be present in the cells composing the tissue but also must be shown to be coded for, synthesized, and secreted by these cells. Second, there must be some local mechanism for the control of the production of angiotensin II, the final product of this pathway. In the vasculature, the first of these premises probably does not hold strictly. Although The development of clinically useful renin inhibitors has been less successful than that of angiotensin converting enzyme inhibitors. However, with the observation that angiotensinogen is linked to hypertension, renin inhibitors become a more attractive therapeutic candidate. The new information summarized above concerning the protein structure and active site residues will permit an extensive exploitation of structure-activity relationship in inhibitor design. Some of these newly designed inhibitors are under clinical testing.'05 Restenosis After Angioplasty Recently, the role of the renin-angiotensin system in supporting myointimal proliferation following angioplasty was assessed in the rat model using angiotensin converting enzyme inhibitors. Initial results were impressive: Neointimal formation was inhibited by 60% when cilazapril was administered 6 days before initial injury.1"0 Subsequent research has shown that the ability of angiotensin converting enzyme inhibitors to atformation."' The AT, receptor antagonist losartan is even more effective because it inhibits both proliferation and migration of smooth muscle cells, whereas angiotensin converting enzyme inhibitors only block migration.112 Despite these striking results in rats, the use of angiotensin converting enzyme inhibitors in primates to inhibit neointimal growth has been disappointing. Hanson et al"l3 administered cilazapril to baboons who had undergone three different procedures to induce vascular lesion formation. They found no beneficial effect of cilazapril on neointimal thickening after 3 months. This has been confirmed in the MER-CATOR study, in which long-term administration of cilazapril did not prevent restenosis or improve clinical outcome after angioplasty in a multicenter, randomized trial.14 Thus, the role of the renin-angiotensin system in restenosis after vessel injury may be species specific.
Cardiac Hypertrophy
A possible role for the renin-angiotensin system in mediating pathological cardiac growth derives from the observation that angiotensin converting enzyme inhibitors can prevent or reverse hypertensive cardiac hypertrophy.1"5 These effects appear ultimately to be caused by angiotensin II, which has direct inotropic and chronotropic effects on myocardial cells,96 increases DNA turnover and protein synthesis in isolated atria and ventricles,1"6 and increases connective tissue deposition.1"7 There is strong evidence for a local reninangiotensin system in the heart,96 with only angiotensin converting enzyme mRNA expression questionable. How much of the angiotensin II that affects cardiac growth is produced locally is not yet known, but preliminary evidence suggests that the local renin-angiotensin system may be important. In spontaneously hypertensive rats, which develop marked cardiac hypertrophy, both renin and angiotensinogen mRNA are increased in the myocardium compared with that in normotensive rats.96 Angiotensinogen gene expression is also transiently increased in the acutely hypertrophying portion of the left ventricle after coronary occlusion.18 Finally, angiotensin converting enzyme inhibitors administered at a concentration that does not alter systemic blood pressure cause prevention and regression of cardiac hypertrophy in response to aortic banding."5 The specific molecular mechanisms by which the renin-angiotensin system is activated and contributes to cardiac hypertrophy are being sought.
Ventricular Remodeling
There is both clinical and experimental evidence of ventricular remodeling after myocardial infarction.'"9 The infarcted segment with akinetic and dyskinetic areas expands and the noninfarcted area undergoes compensatory hypertrophy, probably due to mechanisms similar to those involved in volume-overload hypertrophy resulting from changes in wall stresses and wall stretching.1"9 The net effect is a dilatation of the ventricle in moderate-sized or 
